Latest Cash Flow News

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

Energy Resources of Australia reported a $47.1 million cash outflow from operations and a $75.4 million investment spend in the September quarter, reducing cash reserves to $108.3 million.

Catapult Sports is set to acquire German soccer analytics innovator IMPECT, backed by a A$150 million equity raise, enhancing its global sports technology platform with proprietary scouting insights.

Finder Energy has secured half of the development funding for its KTJ oil project in Timor-Leste through a farmin agreement with TIMOR GAP, alongside an independent resource upgrade that strengthens the project's outlook for first oil by 2027.

Western Gold Resources has secured key approvals, funding, and contracts to fast-track its Gold Duke Project in Western Australia towards near-term gold production.

Toubani Resources has locked in a comprehensive A$395 million funding package, fully financing the development of its Kobada Gold Project in Mali and positioning itself as a future high-margin West African gold producer.

Pacgold Limited announces acquisition and phased restart of the White Dam gold project, targeting near-term production and resource expansion with a $12.4 million funding plan.

Polymetals Resources has advanced its Endeavor Mine ramp-up, producing over 15,000 tonnes of concentrates and scheduling its first zinc shipment. The company also reduced debt and strengthened its cash position, signaling progress toward steady-state operations.

Pacgold Limited has raised $13 million through a two-tranche placement to acquire and restart the White Dam Gold Project, aiming for near-term production and exploration growth.

Buru Energy secured key government approvals and identified a promising new gas prospect beneath its Rafael field, while raising $4.4 million to fund development activities. The company is gearing up for a Final Investment Decision in 3Q 2026, aiming for first material cash flow by 2028.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Medical Developments International reported a strong start to FY26 with significant revenue growth driven by increased Penthrox volumes and pricing improvements in Australia, alongside steady European demand and progress on paediatric label approvals.